This communique outlines key discussion outcomes on the potential neural tube defect (NTD) safety signal in women taking dolutegravir (DTG) at conception and a joint position on behalf of women for access to optimal HIV treatment and prevention.
Communique of the Kigali Dolutegravir Stakeholder Meeting of African Women Living with HIV
Comments